The use of fentanyl in pain management in head and neck cancer patients: a narrative review

Abstract

Background:

Head and neck (H&N) cancers account for about 5% of all malignant tumours. Pain is one of the most feared consequences of H&N neoplasms and is experienced by up to 80% of patients and worsens their quality of life inhibiting speaking, eating, drinking or swallowing. Nevertheless, pain is still often underestimated and undertreated.

Objectives:

The role of opioids in cancer pain has been well established but evidences about the role and the relative effectiveness of opioids such as fentanyl in the context of H&N cancer pain remains unclear.

Methods:

A literature review based on the guidance of the Centre for Reviews and Dissemination was conducted. An iterative approach was used starting with an electronic search in the MEDLINE database. The search terms ((‘Neoplasms’[Mesh]) AND ‘Head and Neck Neoplasms’[Mesh]) AND ‘Fentanyl’[Mesh] were used.

Results:

A total of 18 publications were found by the first performed search on PubMed. Other publications concordant with our aim were found by cross-reference. Considering inclusion and exclusion criteria for our review, eight papers resulted eligible for analysis.

Conclusion:

Fentanyl transdermal therapeutic system (TTS) seems to be an important option, thanks to the way of administration, the good safety and tolerability profiles to control baseline pain. For breakthrough cancer pain (BTcP), several formulations of transmucosal fentanyl are available. All the formulations seem to be active and safety but we lack head-to-head studies of fentanyl versus other strong opioids, as well as with different formulation of fentanyl, particularly for BTcP where H&N cancer population is very poorly represented.

Keywords

Head and neck cancer pain fentanyl breakthrough pain opioids

Get full access to this article

View all access options for this article.

References

Higginson

Hearn

Murtagh

. Epidemiology of cancer pain. In: Sykes

Bennett

Yuan

C-S

(eds) Clinical pain management: cancer pain, 2nd edn. London: Hodder Arnold, 2008, pp. 13–26.

Bernabei

Gambassi

Lapane

et al . Management of pain in elderly patients with cancer: SAGE study group. Systematic assessment of geriatric drug use via epidemiology. JAMA 1998; 279(23): 1877–1882.

Portenoy

. Treatment of cancer pain. Lancet 2011; 377(9784): 2236–2247.

Van den Beuken-van Everdingen

de Rijke

Kessels

et al . Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007; 18: 1437–1449.

O’Connor

Bisson

Asplin

et al . Retrospective analysis of self-reporting pain scores and pain management during head and neck IMRT radiotherapy: a single institution experience. Radiography 2017; 23(2): 103–106.

Baxi

Fury

Ganly

et al . Ten years of progress in head and neck cancers. J Natl Compr Canc Netw 2012; 10(7): 806–810.

Elting

Keefe

Sonis

et al . Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer 2008; 113(10): 2704–2713.

Trotti

Bellm

Epstein

et al . Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 2003; 66: 253–262.

Schindler

Denaro

Russi

et al . Dysphagia in head and neck cancer patients treated with radiotherapy and systemic therapies: literature review and consensus. Crit Rev Oncol Hematol 2015; 96(2): 372–384.

10.

Yazbeck

Villaruz

Haley

et al . Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung). Cancer J 2013; 19(3): 231–237.

11.

Armstrong

McCaffrey

. The effects of mucositis on quality of life in patients with head and neck cancer. Clin J Oncol Nurs 2005; 10: 53–56.

12.

Grond

Zech

Schug

et al . Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 1991; 6(7): 411–422.

13.

World Health Organization. Cancer pain relief, 2nd edn. Geneva: World Health Organization, 1996.

14.

Carlson

. Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review. J Pain Res 2016; 9: 515–534.

15.

Kestenbaum

Vilches

Messersmith

et al . Alternative routes to oral opioid administration in palliative care: a review and clinical summary. Pain Med 2014; 15(7): 1129–1153.

16.

Portenoy

Hagen

. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41(3): 273–281.

17.

Mercadante

. Pharmacotherapy for breakthrough cancer pain. Drugs 2012; 72: 181–190.

18.

Bhatnagar

Upadhyay

Mishra

. Prevalence and characteristics of breakthrough pain in patients with head and neck cancer: a cross-sectional study. J Palliat Med 2010; 13: 291–295.

19.

Caraceni

Hanks

Kaasa

et al . Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13(2): e58–e68.

20.

Ripamonti

Santini

Maranzano

et al . Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol 2012; 23(suppl 7): vii139–vii154.

21.

Benedetti

Brock

Cleeland

et al . NCCN practice guidelines for cancer pain. Oncology 2000; 14(11A): 135–150.

22.

Hess

Stiebler

Herz

. Pharmacokinetics of fentanyl in man and the rabbit. Eur J Clin Pharmacol 1972; 4(3): 137–141.

23.

Fallon

Reale

Davies

et al . Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol 2011; 9: 224–231.

24.

Gourlay

Kowalski

Plummer

et al . The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems. Pain 1990; 40(1): 21–28.

25.

Miser

AW1

Narang

Dothage

et al . Transdermal fentanyl for pain control in patients with cancer. Pain 1989; 37: 15–21.

26.

Alberts

Smith

Parikh

et al . Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl. Pain Manag 2016; 6(5): 427–434.

27.

Mercadante

Portenoy

. Breakthrough cancer pain: twenty-five years of study. Pain 2016; 157(12): 2657–2663.

28.

Schug

Ting

. Fentanyl formulations in the management of pain: an update. Drugs 2017; 77(7): 747–763.

29.

Mystakidou

Katsouda

Parpa

et al . Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. Am J Hosp Palliat Care 2005; 22: 228–232.

30.

Systematic reviews: CRD’s guidance for undertaking reviews in healthcare . York: Centre for Reviews and Dissemination, 2009.

31.

Higginson

Gao

. Opioid prescribing for cancer pain during the last 3 months of life: associated factors and 9-year trends in a nationwide United Kingdom cohort study. J Clin Oncol 2012; 30: 4373–4379.

32.

Grond

Zech

Lehmann

et al . Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain 1997; 69: 191–198.

33.

Haumann

Geurts

van Kuijk

et al . Methadone is superior to fentanyl in treating neuropathic pain in patients with head-and-neck cancer. Eur J Cancer 2016; 65: 121–129.

34.

Chang

Lin

et al . Transdermal fentanyl for pain caused by radiotherapy in head and neck cancer patients treated in an outpatient setting: a multicenter trial in Taiwan. Jpn J Clin Oncol 2010; 40(4): 307–312.

35.

Guo

Zhou

et al . Transdermal fentanyl for pain due to chemoradiotherapy-induced oral mucositis in nasopharyngeal cancer patients: evaluating efficacy, safety, and improvement in quality of life. Drug Des Devel Ther 2014; 12(8): 497–503.

36.

Konopka-Filippow

Zabrocka

Wójtowicz

et al . Pain management during radiotherapy and radiochemotherapy in oropharyngeal cancer patients: single-institution experience. Int Dent J 2015; 65(5): 242–248.

37.

Simon

Schwartzberg

. A review of rapid-onset opioids for breakthrough pain in patients with cancer. J Opioid Manage 2014; 10: 207–215.

38.

Chang

Roeland

Atayee

et al . Transmucosal immediate-release fentanyl for breakthrough cancer pain: opportunities and challenges for use in palliative care. J Pain Palliat Care Pharmacother 2015; 29(3): 247–260.

39.

Pignon

Fernandez

Ayasso

et al . Impact of radiation oncology practice on pain: a cross-sectional survey. Int J Radiat Oncol Biol Phys 2004; 60: 1204–1210.

40.

D’Ambrosio

Horwitz

et al . Does treatment interruption affect outcome after radiotherapy for prostate cancer? Int J Radiat Oncol Biol Phys 2008; 72: 1402–1407.

41.

Kwong

Sham

Chua

et al . The effect of interruptions and prolonged treatment time in radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1997; 39: 703–710.

42.

Mazzola

Ricchetti

Fiorentino

et al . Fentanyl pectin nasal spray for painful mucositis in head and neck cancers during intensity-modulated radiation therapy with or without chemotherapy. Clin Transl Oncol 2017; 19(5): 593–598.

43.

Bossi

Locati

Bergamini

et al . Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer. Oral Oncol 2014; 50(9): 884–887.

44.

Mercadante

Marchetti

Cuomo

et al . Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group. Support Care Cancer 2016; 24(2): 961–968.

45.

Mercadante

Adile

Cuomo

et al . Fentanyl buccal tablet vs. oral morphine in doses proportional to the basal opioid regimen for the management of breakthrough cancer pain: a randomized, crossover, comparison study. J Pain Symptom Manage 2015; 50(5): 579–586.